Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
STAMFORD, Conn., Oct. 27, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, November 3, 2016, at 4:30 p.m. ET to report third quarter 2016 financial results and provide a corporate update.
To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 90388150. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.
An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Steve Silver Stern Investor Relations 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
